Clinical Investigation to Assess the Efficacy and the Safety of VisuXL® Gel Administered in Patients Affected by Moderate DED

Dry Eye Syndromes Clinical Trial

Official title:

Clinical Investigation to Assess the Efficacy and the Safety of VisuXL® Ophthalmic Gel Administered in Patients Affected by Moderate Dry Eye Disease (DED): a Randomized, Cross Over, Double Blind Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04485533
• Other study ID #: VF-OS-004/2019
• Status: Active, not recruiting
• Phase: N/A
• Start date: July 6, 2020
• Est. completion date: April 30, 2021

Study information

• Verified date: July 2020
• Source: VISUfarma SpA
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a post-market, european multicenter study. This is a randomized, cross-over, double blind study with competitive enrolment, aimed to enroll a total of 90 patients with a diagnosis of moderate dry eye disease (DED).

Description:

The purpose of the study is to evaluate the non-inferiority of the new treatment versus the comparator.

Patients, after signing the Informed Consent, will enter into a 1-week screening phase during which the baseline tests will be conducted.

Baseline (V0), Day 30 ± 1 week (V1), Day 38 ± 2 days (V2), Day 68 ±1 week (V3) of treatment.

Between V1 and V2 one week of wash out should be performed. Of note, all ophthalmologic evaluations listed in the Flow-Chart will be performed on both eyes of the patient.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 90
• Est. completion date: April 30, 2021
• Est. primary completion date: April 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient Informed consent form (ICF) signed.

• Males and Females aged =18 years at the time of the signature of ICF.

• Patients with moderate dry eye disease (DED) according to IDEEL questionnaire (score =51 and =64) and diagnosed at least 3 months before enrolment.

• No use of other tear substitutes in the 5 days prior to enrolment, except for refresh solutions.

• TBUT value <6 sec.

• Willing to follow all study procedures, including attending all site visits, tests and examinations.

• Women must agree to be using two forms of effective contraception, be post-menopausal from at least 12 months prior to trial entry, or surgically sterile.

Exclusion Criteria:

• Patients with a mild or severe dry eye disease (DED) according to IDEEL questionnaire (score =50 and =65, respectively).

• Use of ophthalmologic products in the 14 days prior to enrolment, except for refresh solutions and stable glaucoma treatment.

• No previous history or presence of any disease involving cornea or conjunctiva.

• Sj?gren syndrome.

• History or active cicatricial conjunctivitis.

• History of ocular surface burns.

• Use of contact lenses.

• Corneal refractive surgery 1 year post-operative.

• Any ocular surgery in the previous 3 months preceding the study.

• Unstable glaucoma (treatment changes in the last year).

• Any macular or retinal disease that could impact visual acuity.

• Best corrected visual acuity (BCVA) below 20/40.

• Blepharitis treatment started less than 3 months before enrolment.

• Neurological, neurodegenerative or cerebrovascular conditions.

• Any clinically significant history of serious digestive tract, liver, kidney, cardiovascular, cancer or hematological disease.

• Unstable treatment with systemic medications, such as diuretics, antihistamines, antidepressants, psychotropics, cholesterol lowering agents and beta-blockers.

• Known hypersensitivity to one of the administered products.

• Known drug and/or alcohol abuse.

• Mental incapacity that precludes adequate understanding or cooperation.

• Participation in another investigational study or blood donation within 1 month prior to ICF signature.

Related Conditions & MeSH terms

• Dry Eye Syndromes
• Keratoconjunctivitis Sicca

Intervention

Device:
• VisuXL® Gel
VisuXL® ophthalmic gel, available in a multidose 10ml bottle without preservatives based on Coenzyme Q10, Vitamin E TPGS and cross-linked sodium carboxymethylcellulose. Dose/dosage: 1 drop per eye twice a day.
• HYLO®
HYLO® ophthalmic solution, a phosphate- and preservative-free sterile eye drops containing 2 mg/ml of hyaluronic acid sodium salt, a citrate buffer, sorbitol and water. Dose/dosage: 1 drop per eye twice a day

Locations

Country	Name	City	State
France	Hôpital Morvan	Brest	Finistère
Italy	ASST-Santi Paolo e Carlo-Presidio San Paolo	Milano	MI
Spain	Hospital Clínico San Carlos de Madrid	Madrid

Sponsors (1)

Lead Sponsor	Collaborator
VISUfarma SpA

Countries where clinical trial is conducted

France,  Italy,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tear Break-Up Time (TBUT)	To evaluate the effect of treatment with VisuXL® GEL versus HYLO® on the stability of the tear film by Tear Break-Up Time (TBUT) in patients affected by moderate dry eye disease (DED).	through study completion, an average of 2.5 months
Secondary	Stability of the tear film assessed by NIBUT (Non-invasive Break-Up Time)	To evaluate the time-related effects of treatment with VisuXL® GEL versus HYLO® in patients affected by moderate dry eye disease (DED) on Stability of the tear film	through study completion, an average of 2.5 months
Secondary	Functional Visual Acuity (FVA)	To evaluate the time-related effects of treatment with VisuXL® GEL versus HYLO® in patients affected by moderate dry eye disease (DED) on Functional Visual Acuity (FVA)	through study completion, an average of 2.5 months
Secondary	Tear secretion	To evaluate the time-related effects of treatment with VisuXL® GEL versus HYLO® in patients affected by moderate dry eye disease (DED) on Tear secretion	through study completion, an average of 2.5 months
Secondary	Burning, foreign body sensation, itching, and photophobia symptoms of DED assessed by Visual Analogue Scale (10 points VAS)	To evaluate the time-related effects of treatment with VisuXL® GEL versus HYLO® in patients affected by moderate dry eye disease (DED) on Burning, foreign body sensation, itching, and photophobia symptoms of DED.; (VAS: scale where patient has to specify level of satisfaction by indicating a position along a continuous line between two end-points (0 - 10). 0 indicates no satisfaction while 10 represents the highest level).	through study completion, an average of 2.5 months
Secondary	Conjunctival inflammation assessed by staining grade with Van Bijsterveld Scale	To evaluate the time-related effects of treatment with VisuXL® GEL versus HYLO® in patients affected by moderate dry eye disease (DED) on Conjunctival and corneal inflammation	through study completion, an average of 2.5 months
Secondary	Corneal inflammation assessed by staining grade with SICCA Scale	To evaluate the time-related effects of treatment with VisuXL® GEL versus HYLO® in patients affected by moderate dry eye disease (DED) on Conjunctival and corneal inflammation	through study completion, an average of 2.5 months
Secondary	Impact of DED on Everyday Life assessed by means of Quality of Life questionnaire IDEEL	To evaluate the time-related effects of treatment with VisuXL® GEL versus HYLO® in patients affected by moderate dry eye disease (DED) on Impact of DED on Everyday Life assessed by means of Quality of Life questionnaire IDEEL	through study completion, an average of 2.5 months
Secondary	Each of the three modules that are part of IDEEL questionnaire	To evaluate the time-related effects of treatment with VisuXL® GEL versus HYLO® in patients affected by moderate dry eye disease (DED) on Each of the three modules that are part of IDEEL questionnaire	through study completion, an average of 2.5 months
Secondary	Number of participants with treatment-related Adverse Events and Adverse Device Events assessed in a descriptive way	To evaluate the time-related effects of treatment with VisuXL® GEL versus HYLO® in patients affected by moderate dry eye disease (DED) on Medical devices' safety and tolerability: Allergy to any device compound; Any other adverse event (AE); Adverse device effects (ADEs) -Undetected/unforeseen manufacturing ADE which might bring to application procedure errors -; Contamination of the device nozzle and possibility to contaminate both eyes; Interaction with any other permitted local administered therapy; Vital signs: blood pressure (BP), heart rate (HR), respiratory rate (RR)	through study completion, an average of 2.5 months